These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 33309774)

  • 1. Cobimetinib plus atezolizumab in BRAF
    Gogas H; Dréno B; Larkin J; Demidov L; Stroyakovskiy D; Eroglu Z; Francesco Ferrucci P; Pigozzo J; Rutkowski P; Mackiewicz J; Rooney I; Voulgari A; Troutman S; Pitcher B; Guo Y; Yan Y; Castro M; Mulla S; Flaherty K; Arance A
    Ann Oncol; 2021 Mar; 32(3):384-394. PubMed ID: 33309774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
    Dummer R; Queirolo P; Abajo Guijarro AM; Hu Y; Wang D; de Azevedo SJ; Robert C; Ascierto PA; Chiarion-Sileni V; Pronzato P; Spagnolo F; Mujika Eizmendi K; Liszkay G; de la Cruz Merino L; Tawbi H
    Lancet Oncol; 2022 Sep; 23(9):1145-1155. PubMed ID: 35940183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
    Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
    Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF
    Ascierto PA; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Zhukova N; Schachter J; Yan Y; Caro I; Hertig C; Xue C; Kusters L; McArthur GA; Gutzmer R
    Lancet Oncol; 2023 Jan; 24(1):33-44. PubMed ID: 36460017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF
    Robert C; Lewis KD; Gutzmer R; Stroyakovskiy D; Gogas H; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Caro I; Forbes H; Shah K; Yan Y; Li H; McArthur GA; Ascierto PA
    Ann Oncol; 2022 May; 33(5):544-555. PubMed ID: 35131452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
    Dummer R; Queirolo P; Gerard Duhard P; Hu Y; Wang D; de Azevedo SJ; Robert C; Ascierto PA; Chiarion-Sileni V; Pronzato P; Spagnolo F; Mujika Eizmendi K; Liszkay G; de la Cruz Merino L; Tawbi H
    Lancet Oncol; 2023 Dec; 24(12):e461-e471. PubMed ID: 37459873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
    Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
    Schmitt AM; Dumas L; Larkin J
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
    Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
    Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma.
    Cai C; Yunusa I; Tarhini A
    JAMA Netw Open; 2021 Nov; 4(11):e2132262. PubMed ID: 34762112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF
    Sandhu S; Atkinson V; Cao MG; Medina T; Rivas AS; Menzies AM; Caro I; Roberts L; Song Y; Yan Y; Guo Y; Xue C; Long GV
    Eur J Cancer; 2023 Jan; 178():180-190. PubMed ID: 36455412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
    Sullivan RJ; Hamid O; Gonzalez R; Infante JR; Patel MR; Hodi FS; Lewis KD; Tawbi HA; Hernandez G; Wongchenko MJ; Chang Y; Roberts L; Ballinger M; Yan Y; Cha E; Hwu P
    Nat Med; 2019 Jun; 25(6):929-935. PubMed ID: 31171876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
    Brufsky A; Kim SB; Zvirbule Ž; Eniu A; Mebis J; Sohn JH; Wongchenko M; Chohan S; Amin R; Yan Y; McNally V; Miles D; Loi S
    Ann Oncol; 2021 May; 32(5):652-660. PubMed ID: 33539944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
    Livingstone E; Gogas H; Kandolf-Sekulovic L; Meier F; Eigentler TK; Ziemer M; Terheyden PAM; Gesierich AH; Herbst RA; Kähler KC; Ziogas DC; Mijuskovic Z; Garzarolli M; Garbe C; Roesch A; Ugurel S; Gutzmer R; Grob JJ; Kiecker F; Utikal J; Windemuth-Kieselbach C; Eckhardt S; Zimmer L; Schadendorf D
    Eur J Cancer; 2023 Sep; 190():112941. PubMed ID: 37482012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
    Hellmann MD; Kim TW; Lee CB; Goh BC; Miller WH; Oh DY; Jamal R; Chee CE; Chow LQM; Gainor JF; Desai J; Solomon BJ; Das Thakur M; Pitcher B; Foster P; Hernandez G; Wongchenko MJ; Cha E; Bang YJ; Siu LL; Bendell J
    Ann Oncol; 2019 Jul; 30(7):1134-1142. PubMed ID: 30918950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
    Long GV; Dummer R; Hamid O; Gajewski TF; Caglevic C; Dalle S; Arance A; Carlino MS; Grob JJ; Kim TM; Demidov L; Robert C; Larkin J; Anderson JR; Maleski J; Jones M; Diede SJ; Mitchell TC
    Lancet Oncol; 2019 Aug; 20(8):1083-1097. PubMed ID: 31221619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.